Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration

COPENHAGEN, Denmark & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) announced today that the companies have entered into an oncology research and development collaboration. Together, the companies will evaluate Genmab antibodies and bispecific antibody engineering technologies in combination with Bolt’s proprietary Boltbody™ immune-stimulating antibody...

Click to view original post